Bioprinted tissue therapeutics company Aspect Biosystems has closed a $115 million Series B financing round. The financing was led by Dimension, and included Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture. This builds on… Read More
This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Going paperless – the move to electronic lab… Read More
Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and treat diseases, including cancer. Differences in DNA, RNA, and protein can be identified in individual tissue samples, and even in individual cells. The massive data sets generated from this research have driven advances in data… Read More
Listen to this article on the DDW podcast: DDW Editor, Reece Armstrong, sits down with Brinter CEO Tomi Kalpio to learn about the company’s approach to bioprinting and how it can be used throughout drug discovery. Brinter is a provider of 3D bioprinting solutions based in Turku, Finland and the US. Read More
